A new study published in the Proceedings of the National Academy of Sciences shows that Giroud’s experimental antiviral drug, remdesivir, can be effective in preventing infection with MERS in monkeys and reducing the severity of symptoms. Scientists at the U.S. National Institute of Allergy and Infectious Diseases (NIAID) tested Ridsiewe 24 hours before the infection in the monkeys and 12 hours after infection, and compared them to untreated monkeys in the control group. Six days later, all the untreated animals became ill.
The researchers said the drug appeared to have a disease-prevention effect in monkeys treated with Redcivir before the infection. The monkeys in this group showed no signs of infection, and their levels of the virus in their lungs decreased significantly, with no lung damage.
Monkeys treated after infection were also better than the control group. The researchers found that their condition was less severe, that the level of the virus in the lungs was lower, and that the lung damage improved.
However, Ridsywe has previously been shown to have a protective effect on monkeys infected with the Ebola virus, but this effect has not been transferred to humans.
“It’s not successful on the Ebola virus, but there are some indications that it may have been successful in coronavirus,” DR Anthony Fauci, director of NIAID, said in a recent interview. “